Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819727 | 0.86 | PARP10 (0.41) | SLC2A1 | |
| SCHEMBL19291800 | 0.77 | CHRM2 (0.47) | KMT2ACARM1PRMT6MEN1SLC2A1 | |
| SCHEMBL2204692 | 0.77 | CHRM2 (0.47) | KMT2ACARM1PRMT6MEN1SLC2A1 | |
| SCHEMBL25819673 | 0.77 | CHRM2 (0.47) | KMT2ACARM1PRMT6MEN1SLC2A1 | |
| SCHEMBL25819726 | 0.77 | PARP10 (0.43) | SLC2A1 | |
| SCHEMBL2208665 | 0.77 | KMT2A (0.37) | KMT2AMEN1ACACBACACA | |
| SCHEMBL25819721 | 0.76 | THRA (0.38) | CARM1PRMT6SLC2A1ACACBACACA | |
| SCHEMBL25819677 | 0.76 | CHRM2 (0.48) | KMT2ACARM1PRMT6MEN1SLC2A1 | |
| SCHEMBL4568839 | 0.75 | PARP15 (0.42) | SLC2A1 | |
| SCHEMBL2204386 | 0.74 | PARP10 (0.44) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3008/4885CTSS 3012/4885CTSK 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.